ANNEX

In Annex VI to Regulation (EC) No 1272/2008, Table 3 of Part 3 is amended as follows:

(1) the following entries are inserted:

Index	Chem		CAS	Classi	fication	Label	ling			idNotes
No	name	No	No	Class and Catego	Code(ory	d Pictog e ßi gnal s)Word Code(statem Code(ehtazar	d M- efactor s)and	Limits s
[•] 007-0.	3 0i00e 3 acid % [C ≤ 70 %]	231-71	47 -2 97-3	Code(793. Liq. 3 Acute Tox. 3 Skin Corr. 1A	s) H272 H331 H314	GHS03 GHS05 Dgr	5H331	EUH0'	ATE ATE Ox. Liq. 3; H272: $C \ge 65\%$ inhalat ATE = 2,65 mg/L (vapou Skin Corr. 1A; H314: $C \ge 20\%$ Skin Corr. 1B; H314: $5\% \le C \le 20\%$	
⁶ 014-04	4840000 fibres (with diamet < 3 µm, length > 5 µm and aspect ratio $\ge 3:1$)		14 8 9-21 308076		B H350i	GHS08 Dgr	3H350i'			

'014-()4 9i00e0 trimeth		Asabase) iyl)silan		H317	GHS07 Wng	'H317'			
ʻ014-(6-(2- methoz	cyethox cyethox 2,5,7,10- a-6-	y)vinyls y)-6-	R ∉pr.	H360F	ØHS08 Dgr	3H360F	D'		
ʻ016-(9 8in@tB disulph		60 4-92	Liq. 2 Acute Tox. 3 Acute Tox. 3 STOT SE 3 STOT	H319 H317 H400 H410	tory	5H331 3H301	tory	inhalat ATE = 5 mg/L (vapou oral: ATE = 190 mg/ kg bw M = 1 M = 10'	
'029-(X	2gradula copper [partic length: from 0,9 mm to 6,0 mm; particle width: from 0,494 to 0,949 mm]	; le	9 7-6 40-5	0A&uatio Chronio 2	2H411 C	GHS09	9H411'			

			·						
·029-02	2 5is(0 75	239-70	33-#2600) 18 9418.	H228	GHS02	2H228	oral:	
	hydrox	y- <i>N</i> -	15627-	08905.1	H302	GHS07	'H302	ATE	
	nitroso	cyclohe	xylamir	atoute (ЮНЗбрр	eGHS08	H373(live	r) $= 360$	
	bis(N-			Tox.	(liver)			mg/	
	cycloh	exvl-		4	H318	GHS09		kg bw	
	diazeni			STOT	H400	Dgr		M = 1	
	dioxy)			RE 2	H410	Dgi		M = 1	
					11410			1'	
	copper	P		Eye				1	
	[Cu-			Dam.					
	HDO]			1					
				Aquati	с				
				Acute					
				1					
				Aquati					
				Chroni	c				
				1					
·050 0	24:00-0	t 2 2-88	2010 1	D Q	U2605	CHEAG			
030-0.	2			L 1			3H360D		
	dilaura		[1]	1B	H372	Dgr	H372		
	[1]		195648-		(immu		(immune		
	stannai		[2]	RE 1	system)	system)'		
	dioctyl								
	bis(coc								
	acylox	y)							
	derivs.								
	[2]								
·(01 0	na:100-0	105C00	A .a.1., 20	Sama 1	101250	CHEOG	11250	Cara 1	D .
001-0		0 2<i>605</i>/,8 8				GHS08		Carc. 1H	з;
	albenz	o[<i>a</i> , <i>l</i>]py	rene	Muta.	H341	Dgr	H341	H350:	
				2				$C \geq$	
								0,001	
								%'	
⁶⁰³⁻²	3ipc0na	zole	125225	R897	H360D	GHS08	3H360D	oral:	
000 -	(ISO);		115850		H302	GHS07		ATE	
		SR,5RS;				GHS09		= 500	
	(4-	$p_{\Lambda, 3\Lambda 5}$	11113,2201	Tox.					
		benzyl)-	5	10x. 4	(eyes, skin,	Dgr	(eyes,	mg/	
			5-		,		skin,	kg bw	
	isoprop			STOT	liver)		liver)	M =	
	(1 <i>H</i> -1,			RE 2	H410		H410	100'	
	triazol-			Aquati					
	ylmeth	yl)cyclo	pentanc		c				
				1					
·603-2	3 8:00- 9	205-59	41-473-24	- R enr	H360F	IGHS08	3H360FD'		
005 2.	(2-		1,5 21	1B	115001	Dgr			
		vyethox	v)ethvl)			251			
			y Jeury I)	cuici,					
	tetragly	yille							
·603-2	3 19a0104	utrazol	76738-	6₽e0 r.	H361d	GHS08	3H361d	inhalatio	on:
	(ISO);			2	H332	GHS07		ATE	
		RS 1		Acute	H302	GHS09		=	
	(2RS3)				11004	01100/			
	(2RS,3)	1.5)-1-			H319	Wno	H310	313	
	(4-	Í	1.1	Tox.	H319 H400	Wng	H319 H410	3,13	
	(4-	phenyl)-	4,4-		H319 H400 H410	Wng	H319 H410	3,13 mg/L (dusts	

	(1 <i>H</i> -1,, triazol- yl)pent ol	1-		Acute Tox. 4 Eye Irrit. 2 Aquati Acute 1 Aquati Chroni 1	с				or mists) oral: ATE = 490 mg/ kg bw M = 10 M = 10'	
`603-24 X	4 D,-DO- bis(bro diol	221-96 mometh	7 3-27 96-9 nyl)prop			GHS08 Dgr	3H350 H340'			
·603-24	(2E)-3	ylocta-2		- S kin Sens. 1	H317	GHS07 Wng	'H317'			
·605-04	(4-tert-	201-28 enzyl)pr		1B	H360F	dGHS08 Dgr	3H360F	d'		
	thioeth (ISO); S- ethyl (4- chloro- methyl S- ethyl 4- chloro- tolylox	-2- phenoxy ythioac	y)ethane etate	Tox. 4 STOT RE. 2 Aquati Acute thioate Aquati Chroni 1	H410 c c c	GHS07 GHS08 GHS09 Wng	3H373 9(liver) H410		oral: ATE = 450 mg/ kg bw M = 10 M = 10'	
'607 - 7-	4 0 i i300 phthala	t 3/4 8-52 ite	227 554-	Жер т. 1В	H360F	IGHS08 Dgr	3H360F	D'		
'607-7	yl)met (2,2- difluor one;	yridin-	mino}f	Tox. 4 STOT RE 2	Н400 Н410 € <i>Н</i>)- с	GHS07 GHS08 GHS09 Wng	3H373	e)	oral: ATE = 500 mg/ kg bw M = 10 M = 10'	

·(07.7	10.00		217014	02-14	-11400	CHEOR	11410		M	
X	4 thi@0 ca methyl		-31/813	Acute	сн400 H410	GHS09 Wng	H410		M = 1000	
Λ	(ISO);			1	11410	wing			M =	
	methyl			Aquati	c				1000'	
	4-			Chroni					1000	
	[(4,5-			1	C					
	dihydro	-3-		1						
	methox									
	methyl									
		<i>I</i> -1,2,4-								
	triazol-									
		onylsul	famovl]	-5-						
		thiophe		2						
	carbox									
		ľ	70 22	401 :	11214	OH COL	11214	DIUIO	717	<u> </u>
*60 7-7	4 B- 00-5	201-19	6/9-33-		H314	GHS05	H314	EUH07	/1	
	(+)-			Corr.	H318	Dgr				
	lactic			1C						
	acid;			Eye						
	(2S)-2-			Dam.						
		ypropai	1010	1						
	acid									
'607-7	42-00-0	221-49	BB21-6	IFI∕am.	H226	GHS02	2H226	EUH07	7 i nhalat	ion:
	methoy	cyethyl		Liq. 3	H341	GHS05	5H341		ATE	
	acrylat	e		Muta.	H360F	IGHS06	5H360F	D	= 2,7	
				2	H331	GHS08	H331		mg/L	
				Repr.	H302	Dgr	H302		(vapou	rs)
				1B	H314		H314		oral:	
				Acute	H318		H317		ATE	
				Tox.	H317				= 404	
				3					mg/	
				Acute					kg	
				Tox.					bw'	
				4						
				Skin						
				Corr.						
				1C						
				Eye						
				Dam.						
				1						
				Skin						
				Sens.						
				1						
[•] 607-7	4 51-00 x6	1206-05	82-978-12	-Hye	H318	GHS05	H318			B'
	acid			Dam.	H317	GHS07				
	%			1		Dgr				
				Skin		C				
				Sens.						
				1B						
	L		L	L			L			L

607-74		274-35	77 -8 161-	4 2 (aBc. 1		GHS08			inhalat	
	N-			Muta.	H341	GHS07	'H341		ATE	9'
	(hydro	xymethy	yl)glycii	nate;	H332	Dgr	H332		= 3	
		ldehyde		Acute	H302	U	H302		mg/L	
	release			Tox.	H335		H335		(dusts	
	from	u		4	H315		H315		or	
	sodium	1		Acute			H319		mists)	
	<i>N</i> -			Tox.	H317		H317		oral:	
	(hydro	xymethy	yl)glycii	n 4 te]					ATE	
				STOT					=	
				SE 3					1100	
				Skin					mg/	
				Irrit.					kg bw	
				2					Kg UW	
				Eye						
				Irrit.						
				2						
				Skin						
				Sens.						
				1						
(11 1	0.1 -0.0		((()))		11220	CHOO	11220		1	
511-12	3 pe0assi		66603-		H228	GHS02			oral:	
	(oxido-			Sol. 1	H301	GHS06			ATE	
		cyclohe		Acute	H373	GHS08			= 136	
	cycloh	exylhyd	roxydia	z eos .	(liver)	GHS05	(liver)		mg/	
	1-		-	3	H315	GHS09			kg	
	oxide,			STOT	H318	Dgr	H318		bw'	
	potassi	um		RE 2	H411	0	H411			
	salt;	um		Skin						
				Irrit.						
	[K-									
	HDO]			2						
				Eye						
				Dam.						
				1						
				Aquati						
				Chroni	с					
				2						
512-29	A	0 21211 m10	6-0 06-1	(SB in	H314	GHS05	5H314	EUH07	7M =	
]	etilsulf			Corr.	H318	GHS09			100	
	N-	,		1	H400	Dgr			M =	
	ethyl-Λ	/ N_		Eye	H410	51			1000'	
			agar 1	•	11410				1000	
	umeth	-	ecan-1-	Dam.						
				1						
	aminiu	m		· ·						
	ethyl			Aquati	c					
	ethyl sulfate			Aquati Acute	c					
	ethyl				с					
	ethyl sulfate mecetr			Acute 1						
	ethyl sulfate mecetr ethyl	onium		Acute 1 Aquati	с					
	ethyl sulfate: mecetr ethyl sulphat	onium		Acute 1 Aquati Chroni	с					
	ethyl sulfate mecetr ethyl	onium		Acute 1 Aquati	с					
513-3	ethyl sulfate mecetr ethyl sulphat [MES] 3((2 RO)62	onium e;	141778	Acute 1 Aquati Chroni 1 38403-6	с с H317	GHS07			M = 1	
513-33	ethyl sulfate; mecetr ethyl sulphat [MES] 3(12 RO)62 [4-(4-	onium e;		Acute 1 Aquati Chroni 1	c c	GHS07 GHS09			M = 1 M =	

(1 <i>H</i> tria: yl)r ol; met '613-33 @x@ (ISO 1-(2 {4- (2,6 difl dihy oxa yl]- thia yl}j yl)- [5- met (trif pyra)); - 5- - vdro-1,2- zol-3- 1,3- zol-2- viperidin-1-	azole 100331)-4,5-	Acute 1 Aquati Chroni 1	с с сН410	GHS09 Wng	PH410	M = 1'
	; -)-	oa. <i>O</i>)py	1B Acute Tox. r2dine-2	H330 H301 H372 (H27)8 H400 H410	GHS08 GHS06 GHS09 Dgr	5H301	inhalation: ATE = 0,14 mg/L (dusts or mists) oral: ATE = 221 mg/ kg bw M = 1000 M = 10'
(chl [3-		-1-	1B Acute Tox. 4 Skin	H302 H317 H400 H410	IGHS08 GHS07 GHS09 Dgr		oral: ATE = 500 mg/ kg bw M = 100 M = 100'

	Aquatic Acute 1 Aquatic Chronic 1		
[•] 613-33 4 , 5 0-8 264-84 dichloro-2- octyl-2 <i>H</i> - isothiazol-3- one; [DCOIT]	3548359-84 exite H330 Tox. H302 2 H314 Acute H318 Tox. H317 4 H400 Skin H410 Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1	GHS06 H330 GHS05 H302 GHS09 H314 Dgr H317 H410	EUH07 inhalation: ATE = 0,16 mg/L (dusts or mists) oral: ATE = 567 mg/ kg bw Skin Irrit. 2; H315: 0,025 $\% \leq C < 5$ % Eye Irrit. 2; H319: 0,025 $\% \leq C < 5$ % Eye Irrit. 2; H319: 0,025 $\% \leq C < 3$ % Skin Sens. 1A; H317: $C \geq 0,0015$ % M = 100 M = 100'
'613-33 2 -00-3 methyl-1,2- benzothiazol-3 one; [MBIT]	2527-6644eute H312 Tox. H301 (2 <i>H</i>)-4 H314 Acute H318 Tox. H317 3 H400	GHS06H312 GHS05H301 GHS09H314 Dgr H317 H410	EUH07dermal: ATE = 1100 mg/ kg bw

		Skin Corr. 1C Eye Dam. 1 Skin Sens. 1A Aquati Acute 1 Aquati Chroni 2	с			oral: ATE = 175 mg/ kg bw Skin Sens. 1A; H317: C ≥ 0,0015 % M = 1'
'616-22 8 -00-4 (difluoromethy methyl- <i>N</i> - (3',4',5'- trifluorobiphen yl)pyrazole-4- carboxamide; fluxapyroxad		Hale6 Aquati Acute 1 Aquati Chroni 1	H410 c	GHS09 Wng	H410	M = 1 M = 1'
'616-23 N -00-5 213-10 (hydroxymeth methylolacryla [NMA]	yl)acryla		BH350 H340 H372 (periph nervou system	5	3H350 H340 H372 (periphe nervous system)'	
616-23 5 -00-0 fluoro-1,3- dimethyl- <i>N</i> - [2-(4- methylpentan- yl)phenyl]-1 <i>H</i> pyrazole-4- carboxamide; 2'- [(<i>RS</i>)-1,3- dimethylbutyl] fluoro-1,3- dimethylpyraz carboxanilide; penflufen	2- 	Gar& 2 Aquati Acute 1 Aquati Chroni 1	cH400 H410 c	GHS08 GHS09 Wng		M = 1 M = 1'
'616-23 ip00/-6 icarb (ISO); isopropyl [(2 <i>S</i>)-3- methyl-1- {[1- (4-	140923	9 (<i>ā</i> fd. 2	H351	GHS08 Wng	3H351'	

methy oxobu yl]carb		ethyl]ar	nino}-1	-				
carbox	,5- yl-2- hylsilyl amide)thiophe		H411 c c	GHS08 GHS09 Wng	9H411'		
650-05 Margo ext. [cold- pressed oil of <i>Azadir</i> <i>indica</i> seeds without shells extract with super- critical carborn dioxid	d achta it ied	48-7 696-	2 % eßtati Chroni 3			H412'		

(2)

the entries corresponding to index numbers 007-004-00-1; 014-018-00-1; 015-134-00-5; 015-181-00-1; 050-021-00-4; 050-027-00-7; 082-013-00-1; 603-014-00-0; 603-065-00-9; 605-019-00-3; 607-177-00-9; 607-256-00-8; 607-314-00-2; 609-041-00-4; 609-064-00-X; 613-112-00-5; 613-115-00-1; 613-125-00-6; 613-202-00-4; 613-259-00-5; 616-014-00-0 and 617-006-00-X are replaced by the following entries respectively:

Index	Chem	icEC	CAS	Classi	fication	Labell	ing		Specif	idNotes
No	name	No	No	Hazar	d Hazar	d Pictog	rahhazar	d Suppl	Conc.	Limits,
				Class	statem	estignal	statem	ehłazar	d M-	
				and	Code(s)Word	Code(s)statem	efactor	5
				Catego	ory	Code(s)	Code(
				Code(s)				ATE	
·007-0	0 14i+000c -1	231-71	47-6297-3	7-9 3 x.	H272	GHS03	H272	EUH0'	7 O x.	B'
	acid			Liq. 2	H330	GHS06	5H330		Liq.	
	%			Acute	H314	GHS05	5H314		2;	
	[C >			Tox.		Dgr			H272:	
	70 %]			1					$C \ge$	
				Skin					99 %	
				Corr.					Ox.	
				1A					Liq.	
									3;	
									H272:	
									70 %	

									≤ C < 99 %	
·014-0	1 8e00me [D4]	tBQ9e¥3	16176 5	Bepne; 2 Aquati Chroni 1		GHS08 GHS09 Wng	H361f *** H410		M = 10'	
	methyl (ISO); <i>O</i> -[2- (diethyl wethyl yl] <i>O</i> , <i>O</i> - dimeth phosph	lamino) pyrimid	-6- in-4- ate	Tox. 4 STOT RE 1 Aquati Acute 1 Aquati Chroni 1 Fam. Gas 1 Press.	system H400 cH410 c c c H220 H330 H314)Dgr GHS02 GHS04 GHS06	H372 (nervou system) H410 2H220 H330 5H314		oral: ATE = 1414 mg/ kg bw M = 1000 M = 1000' inhalat ATE = 10	idtî:
				Gas Acute Tox. 1 Skin Corr. 1B Aquati Acute 1	H400 c	GHS05 GHS09 Dgr			ppmV (gases)	
°050-02	2 di61016 4	ഷമങ്	B 12 4Da3	Repr. 1B Acute Tox. 2 STOT RE 1 Aquati Chroni 3	H330 H372 ** H412	GHS08 GHS06 Dgr	8H360D 9H330 H372 ** H412		Repr. 1B; H360 D: $C \ge 0,03$ % inhalat ATE = 0,098 mg/L (dusts or mists)'	ion:
·050-02	2 7- 00-7 ethylhe 10- ethyl-4		2 ⊦\$ 1571-	5%e pr. 1B STOT RE 1	H360D H372 (immu system	GHS09 nÐgr	H360D H372 (immur system)	ne		

dioctyl-7- oxo-8- oxa-3,5- dithia-4- stannatetradecanoa [DOTE] '082-01Beat0-1 231-100742 powder; [particle diameter < 1 mm]	1 39-9 2Re pr. H360F IG HS($\begin{array}{c c c c c c c c c c c c c c c c c c c $
603-012-00-0 203-905-01 butoxyethanol; ethylene glycol monobutyl ether		$\begin{array}{c c c c c c c c c c c c c c c c c c c $
[°] 603-06 <i>б</i> и-00-9 202-98 7-6 bis(2,3- ерохургороху)ber resorcinol diglycidyl ether	Muta. H341 GHS0	$\begin{array}{c ccccc} 08 \text{ H} 350 & \text{dermal:} \\ 06 \text{ H} 341 & \text{ATE} \\ \text{H} 311 & = 300 \\ \text{H} 302 & \text{mg/} \\ \text{H} 315 & \text{kg bw} \\ \text{H} 319 & \text{oral:} \\ \text{H} 317 & \text{ATE} \\ \text{H} 412 & = 500 \\ \text{mg/} \\ \text{kg} \\ \text{bw'} \end{array}$
⁶⁰⁷⁻¹ 7 friððn 9r 401- 190-0 methyl (ISO);	RE 2 H317 GHS0	08 H373 M = 07 H317 100 09 H410 100

	methyl 2-[<i>N</i> - (4- methox methyl- triazin-2 yl)- <i>N</i> - methylo	-1,3,5- 2-	oylsulfa	Skin Sens. 1 Aquati Acute 1 Aquati nddyt]bi	c	Wng		M = 100'
`607-2:	56z0038t (ISO); methyl (E)-2- {2- [6-(2- cyanop yloxy]p methox	henoxy henyl}	-3-	Tox. 3 Aquati Acute 1	c	GHS06 GHS09 Dgr		inhalation: ATE = $0,7$ mg/L (dusts or mists) M = 10 M = 10'
[•] 607-3	l #10062 (ISO); (<i>RS</i>)-2- ethoxy- dihydro dimethy yl methan	2,3-)-3,3- ylbenzo	furan-5	Acute 1 Aquati Chroni	H410 c	GHS09 Wng	PH410	M = 1 M = 1'
·609-04	4 2,-0 0-4 dinitrop			Tox. 3 * Acute Tox. 3 Acute Tox. 2 STOT RE 1 Aquati Acute 1	H311 H300 H372 H400	GHS06 GHS09 Dgr	3H311	dermal: ATE = 300 mg/ kg bw oral: ATE = 30 mg/ kg bw'
`609-00 X	6400tri (ISO); 2-[4- (methy) nitrober cyclohe	lsulfony nzoyl]-	1,3-	2 STOT RE 2	H361d H373 (eyes, nervou csystem H400 H410	-		M = 10 M = 10'

				Aquati Chroni 1						
·613-11	læc00H5n (ISO); 2- octyl-2 isothia: one; [OIT]		12-67530-	20elite Tox. 2 Acute Tox. 3 Acute Tox. 3 Skin Corr. 1 Eye Dam. 1 Skin Sens. 1A Aquati Acute 1 Aquati 1	с	GHS06 GHS09 Dgr	5H311	EUHO	7 Inhalat ATE = $0,27$ mg/L (dusts or mists) dermal ATE = 311 mg/ kg bw oral: ATE = 125 mg/ kg bw Skin Sens. 1A; H 317 : C \geq 0,0015 % M = 100 M = 100'	
·613-11	(ISO); 3- hydrox	a 2∂B -00 y-5- isoxazo		4 Rep r. 2 Acute Tox. 4 Eye Dam. 1 Skin Sens. 1 Aquati Chroni 2	H302 H318 H317 H411	GHS08 GHS07 GHS09 Dgr	7H302 5H318		oral: ATE = 1600 mg/ kg bw'	
·613-12	25eQQ46 (ISO); trans-5 (4- chlorop			0 S quati Acute 1	cH400 H410	GHS09 Wng)H410		M = 1 M = 1'	

cyclohexyl-4- methyl-2- oxo-3- thiazolidine- carboxamide '613-20py00ettozine (ISO); (<i>E</i>)-4,5- dihydro-6- methyl-4- (3- pyridylmethylenean triazin-3(2 <i>H</i>)- one	Repr.H361fdGHS02H410WngAquaticChronic1	8H351 9H361fd H410	M = 1'
⁶¹³⁻²⁵ ³⁷⁻⁰ ⁶¹³⁻²⁵ ³⁷⁻⁰ ⁷ ⁶¹³⁻²⁵ ³⁷⁻⁰ ⁷ ⁶¹⁴² ⁸⁻⁷⁹ ⁷ ⁶⁹ (ISO); reaction mass of: [2,4- dioxo- (2- propyn-1- yl)imidazolidin-3- yl]methyl(1 <i>R</i>)- <i>cis</i> - chrysanthemate; [2,4- dioxo- (2- propyn-1- yl)imidazolidin-3- yl]methyl(1 <i>R</i>)- <i>tran.</i> chrysanthemate	AcuteH332GHS0Tox.H302GHS04H371WngAcute(nervousTox.system;4oral,STOTinhalation)SE 2H400AquaticH410Acute11Aquatic1I	8 H351 7 H332 9 H302 H371 (nervous system; oral, inhalation) H410	inhalation: ATE = 1,4 mg/L (dusts or mists) oral: ATE = 550 mg/ kg bw M = 10 M = 10'
616-0 Humano 2 -49 6 -2 oxime; ethyl methyl ketoxime; ethyl methyl ketone oxime	Acute H312 GHS0	8 H350 6 H312 5 H301 H336 H370 (upper respiratory tract) H373 (blood system) H315 H318 H317	dermal: ATE = 1100 mg/ kg bw oral: ATE = 100 mg/ kg bw'

				Eye Dam. 1 Skin Sens. 1					
'617-0) 6is(0. ,α	-201-27	%0- 43-	3Org.	H242	GHS02	2H242		
Х		ylbenzy			H360D	GHS08	3H360D		
	peroxic	le		F	H315				
				Repr.	H319	GHS09	H319		
				1B	H411	Dgr	H411'		
				Skin					
				Irrit.					
				2					
				Eye					
				Irrit.					
				2					
				Aquati					
				Chroni	c				
				2					

(3) the entries corresponding to index numbers 601-064-00-8 and 607-693-00-4 are deleted.

Changes to legislation:

This version of this Regulation was derived from EUR-Lex on IP completion day (31 December 2020 11:00 p.m.). It has not been amended by the UK since then. Find out more about legislation originating from the EU as published on legislation.gov.uk.